Work

Abstract B014: CRISTAL-APC - A multi-center, open label Phase I/ II study of VP-002, a C-C motif chemokine receptor 1 (CCR1) inhibitor, in combination with nab-paclitaxel and gemcitabine (nPG) in patients with pancreatic ductal adenocarcinoma (PDAC)

Year: 2025

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-b014

Authors: Alexander A. Azizi, Giovanni Codacci Pisanelli, Michael Gill, Helena Rayment, Ruth Okhuarobo, Agata Rohnke, Neel Sharma, Philippa Corrie, Katherine Dempsey, Alimu Dayimu, Nikolaos Demiris, Sabita Islam, Anita Chhabra, Leah Officer-Jones, John Le Quesne, David Chang, Duncan Jodrell, Fieke Froeling, Bristi Basu

Institutions: The Francis Crick Institute, Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cancer Research UK Scotland Institute, University of Glasgow

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415453975

Cites:

Cited by:

Related to: